X4 Pharmaceuticals, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for XFOR, updated each market day.
XFOR AI Sentiment
AI sees no strong directional signal for X4 Pharmaceuticals, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About X4 Pharmaceuticals, Inc. Common Stock
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Sector
Exchange
Market Cap
$370,043,162
Cap Tier
Employees
45
Headquarters
BOSTON, MA
Listed Since
Nov. 16, 2017
Website
XFOR Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
XFOR Volatility
X4 Pharmaceuticals, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
